FDA’s Drug Repurposing Initiative Signals a Shift in Regulatory Strategy

By Darya Lucas

The U.S. Food and Drug Administration (FDA) recently launched a drug repurposing initiative that may signal a shift in how the Agency approaches therapeutic development. Rather than focusing exclusively on novel compounds and first-in-class therapies, the FDA appears increasingly interested in identifying additional uses for existing drugs, particularly where unmet medical needs remain and commercial incentives for further development are limited.

The concept is not new. Physicians have prescribed drugs off-label for decades, and many therapies became successful through secondary or unexpected uses. What appears different now is FDA’s effort to formalize and encourage the process through a more coordinated regulatory framework.

The Agency has recently announced a public-facing initiative seeking input on approved or previously studied drugs that may warrant further evaluation for new indications. In many cases, these therapies already possess substantial safety, manufacturing, and pharmacology data, potentially allowing development programs to move more efficiently than programs involving entirely new drug applications.

FDA’s focus appears directed toward situations where scientific evidence may exist, but financial incentives do not. Many off-patent or lower-revenue therapies may show promise for additional conditions, yet manufacturers often lack sufficient motivation to pursue supplemental approvals. As a result, some drugs remain widely used off-label without updated FDA labeling, which creates challenges involving reimbursement, standardization, and broader clinical adoption.

Evidence, AI, and Compliance Risk

The initiative also aligns with broader regulatory trends. FDA has increasingly emphasized the use of real-world evidence, postmarket data, literature reviews, and modernization of labeling infrastructure as part of its evolving regulatory approach. Drug repurposing fits naturally within that framework because these therapies often already have extensive human exposure data and years of clinical experience.

Artificial intelligence may further accelerate these efforts. AI-driven platforms are increasingly capable of analyzing scientific literature, patient outcomes, genomic data, and adverse event data to identify potential therapeutic relationships that may otherwise remain undiscovered. As these tools become more sophisticated, repurposing may become faster, less expensive, and more accessible to smaller biotech companies and academic researchers.

At the same time, FDA’s willingness to explore regulatory flexibility does not eliminate compliance risk. Existing approval for one indication does not permit unsupported claims for another, and companies pursuing repurposed uses will likely continue to face scrutiny regarding promotional practices and evidentiary support.

“Ultimately, the significance of the FDA’s initiative extends beyond any single therapy. It reflects growing recognition that innovation may come not only from developing new drugs, but also from identifying additional value in therapies that already exist.”
Darya Lucas, Associate Attorney

As healthcare systems continue to face pressure to reduce costs and accelerate patient access, drug repurposing may become an increasingly important part of the pharmaceutical and regulatory landscape.

How Gardner Law Can Help

The FDA’s drug repurposing initiative highlights both opportunity and regulatory complexity, particularly as companies explore new indications for existing drugs, rely on real-world evidence, or seek to translate academic findings into approved uses. While repurposing may reduce certain development burdens, it does not reduce the FDA’s expectations around evidentiary support, labeling accuracy, or promotional compliance.

Gardner Law advises life sciences companies and healthcare organizations on FDA regulatory strategy, drug repurposing pathways, and promotional compliance. We assist clients in assessing repurposing opportunities, evaluating evidentiary standards for supplemental approvals, reviewing proposed indications and labeling language, and managing regulatory risk across clinical development and commercialization. We also provide guidance on communications involving off-label or emerging uses, helping clients navigate regulatory expectations as this landscape continues to evolve.